The number of biotech and pharma professionals taking jobs they’re overqualified for is now over 50%, based on a BioSpace LinkedIn poll. A recruiting firm executive discusses the trend, the reasons behind it and why it doesn’t have to derail careers.

Original title: “Biopharma professionals increasingly accept underemployment”

We explore more of the thematic tracks and sessions featuring in our ECRD 2026 programme. The post Beyond diagnosis and treatment: Delivering holistic care for people living with rare diseases appeared first on EURORDIS-Rare Diseases Europe.

Original title: “Beyond diagnosis and treatment: Delivering holistic care for people living with rare diseases”

Original title: “What Is Raeder Syndrome? The Rare Condition Behind One-Sided Head Pain”

The webinar will explore key findings related to mental health of people living with rare diseases... The post Launch of Rare Barometer survey results: The mental health of people living with a rare or undiagnosed condition and their family members appeared first on EURORDIS-Rare Diseases Europe.

Original title: “Launch of Rare Barometer survey results: The mental health of people living with a rare or undiagnosed condition and their family members”

Homepage for CDC's information on <em>Mycoplasma pneumoniae </em>infections.

Original title: “<em>Mycoplasma pneumoniae</em> Infection”

Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.

Original title: “Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers”

Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.

Original title: “Types of Articles”

/PRNewswire/ -- On Tuesday, the EveryLife Foundation for Rare Diseases (EveryLife Foundation) convened its biennial Scientific Workshop titled, "Making What... WASHINGTON, May 14, 2026 /PRNewswire/ -- On Tuesday, the EveryLife Foundation for Rare Diseases (EveryLife Foundation) convened its biennial Scientific Workshop titled, "Making What Matters Count: Advancing Patient-Centered Rare Disease Therapy Development Methodologies, Tools, and Knowledge Management." First established in 2010, the Scientific Workshop series serves as a forum for the rare disease community to address urgent challenges at the intersection of science and policy. This year's workshop focused on strengthening the application of patient-centered approaches in rare disease therapy development amid a rapidly evolving regulatory landscape. With significant advancements in regulatory science over the past two decades, participants examined how new and existing U.S. Food and Drug Administration (FDA) pathways, guidances, and programs are being applied across the more than 10,000 known rare diseases — highlighting both progress and persistent gaps in consistency, implementation, and access. "Ensuring that patient experience is meaningfully and consistently integrated into therapy development requires not just policy changes, but alignment, coordination, and actionable tools," said Jamie Sullivan, Senior Vice President of Policy and Advocacy for the EveryLife Foundation. In the coming weeks, the EveryLife Foundation will synthesize key findings and recommendations from the workshop to guide its ongoing policy and advocacy efforts, with the goal of advancing a more consistent, transparent, and patient-centered framework for rare disease therapy development.

Original title: “EveryLife Foundation Scientific Workshop Advances Patient-Centered Approaches to Rare Disease Therapy Development”

/PRNewswire/ -- On Tuesday, the EveryLife Foundation for Rare Diseases (EveryLife Foundation) convened its biennial Scientific Workshop titled, "Making What... WASHINGTON, May 14, 2026 /PRNewswire/ -- On Tuesday, the EveryLife Foundation for Rare Diseases (EveryLife Foundation) convened its biennial Scientific Workshop titled, "Making What Matters Count: Advancing Patient-Centered Rare Disease Therapy Development Methodologies, Tools, and Knowledge Management." First established in 2010, the Scientific Workshop series serves as a forum for the rare disease community to address urgent challenges at the intersection of science and policy. This year's workshop focused on strengthening the application of patient-centered approaches in rare disease therapy development amid a rapidly evolving regulatory landscape. With significant advancements in regulatory science over the past two decades, participants examined how new and existing U.S. Food and Drug Administration (FDA) pathways, guidances, and programs are being applied across the more than 10,000 known rare diseases — highlighting both progress and persistent gaps in consistency, implementation, and access. "Ensuring that patient experience is meaningfully and consistently integrated into therapy development requires not just policy changes, but alignment, coordination, and actionable tools," said Jamie Sullivan, Senior Vice President of Policy and Advocacy for the EveryLife Foundation. In the coming weeks, the EveryLife Foundation will synthesize key findings and recommendations from the workshop to guide its ongoing policy and advocacy efforts, with the goal of advancing a more consistent, transparent, and patient-centered framework for rare disease therapy development.

Original title: “EveryLife Foundation Scientific Workshop Advances Patient-Centered Approaches to Rare Disease Therapy Development”

This report describes survey results from backyard flock owners’ attitudes towards avian influenza.

Original title: “Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks — United States, July–December 2025”

Building trust with patient organisations in the misinformation era

Original title: “Kylie’s greatest hits”

This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.

Original title: “[Podcast] Closing the Distance in Cancer Care”

EMA is actively monitoring the ongoing hantavirus outbreak linked to a cruise ship, in coordination with other EU bodies.The virus has been identified as Andes hantavirus, the…

Original title: “EMA actively monitoring cruise ship Hantavirus outbreak”

The ORDR coordinates research, sponsors educational programs for investigators, recommends national research priorities, and funds new studies of these diseases. The office also sponsors the Rare Diseases Clinical Research Network. Recently, the NIH launched a new effort specifically aimed at producing new treatments for rare diseases. The Therapeutics ... The ORDR coordinates research, sponsors educational programs for investigators, recommends national research priorities, and funds new studies of these diseases. The office also sponsors the Rare Diseases Clinical Research Network. Recently, the NIH launched a new effort specifically aimed at producing new treatments for rare diseases. The Therapeutics for Rare and Neglected Diseases program (TRND) is a collaborative effort involving the ORDR, the NIH Chemical Genomics Center, and the National Human Genome Research Institute. A trial may exclude patients using alternative therapies, or patients already enrolled in another trial. These limitations can severely limit the number of eligible patients in an already small population. Rare disease registries, particularly those attempting to understand the course of the disease and treatment patterns, may choose to enroll patients who are already in another trial, or patients pursuing alternative treatments.11 The program will create a drug development pipeline within NIH to stimulate research in rare disease treatments. The goal of the program, which will focus on pre-clinical drug development, will be to support drug research until a drug meets the FDA requirements for an Investigational New Drug (IND) application, at which time the drug will be transferred to an outside organization for further development.6,7 · Despite these efforts to encourage research into rare diseases, significant knowledge gaps still remain, and randomized controlled trials—the gold standard in clinical research—may be extremely difficult to conduct in rare disease populations due to sample size and length of follow-up limitations. Through organized and coordinated clinical investigation systems like patient registries, researchers can accumulate a sufficient number of patients with rare diseases to provide the statistical power needed to study the clinical history of treated and untreated forms of the disease. Registries can also provide basic information, such as data on incidence and treatment patterns, needed for clinical trials of new tests and treatments.10 Two types of registries that are particularly relevant for rare disease research are disease registries and product registries.

Original title: “Patient Registries and Rare Diseases | Applied Clinical Trials Online”

David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One / cancer, David Ross, IPF, Karen Yada Ross, Lung cancer, Natera, Karen continues to advocate for rare diseases such as PH-ILD with a sense of dedication, humility, and compassion. As part of the Pulmovant team, she aspires to make a meaningful difference for these courageous patients.”

Original title: “David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One - OncoDaily”

Omron has appointed Virendra Shelar as CEO of Omron Europe

Original title: “Virendra Shelar”

Making partnership working business as usual

Original title: “Real time”